Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article just published in the journal Cancer has reported an association between the use of androgen deprivation therapy (ADT) and risk for blood clots among men being treated for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, blood clot, hormone, risk, thromboembolism | 9 Comments »
A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, neoadjuvant, outcome, radiation, survival | 12 Comments »
There has long been discussion about the appropriate and inappropriate uses of androgen deprivation therapy (ADT) in the management of progressive prostate cancer. The “New” Prostate Cancer InfoLink has regularly commented on the inherent dangers of using ADT to “manage PSA levels” as opposed to managing a patient’s actual clinical condition.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, therapy, timing | 9 Comments »
Long-term follow-up data have just been published from two studies designed to provide preliminary information on the potential use of very aggressive forms of treatment in men with high-risk categories of prostate cancer.
Filed under: Management, Treatment | Tagged: aggressive, androgen deprivation, docetaxel, hormone, paclitaxel, radiation, taxane, therapy | 7 Comments »
A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, bone, hormone, loss, risedronate, therapy, turnover | Leave a Comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH [...]
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a Comment »
A new — but very small and short-term study — has attempted to assess the baseline prevalence of cognitive impairment in older men treated with androgen deprivation therapy (ADT) and changes in cognitive performance over time.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, cognitive, function, hormone, performance, therapy | 1 Comment »
There is an increasing belief among at least some opinion-leaders in the prostate cancer treatment community that androgen deprivation therapy has been and still is being significantly overused.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, hormone, therapy | 1 Comment »
An important article by Bolla et al. has been published in the New England Journal of Medicine today, together with editorial comment by Albertsen. We advise readers to study this article in conjunction with a second article published today under the heading “Hormone therapy and radiation treatment: a topical update.”
Filed under: Management, Treatment | Tagged: adjuvant, hormone, locally advanced, radiation, therapy | Leave a Comment »
There are three reports in our first daily report for 2009, dealing with issues as varied as genetic profiling for prostate cancer risk, the relative merits of LRP and RALP, and the management of geriatric prostate cancer patients who are on long-term hormone therapy.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: gene, geriatric, hormone, LRP, RALP, risk, SNPs | 10 Comments »
In today’s reports: Zoledronic acid (Zometa) has confirmed it’s impact on skeletal strength in the “real world” Time to recovered of “normal” testosterone levels after ADT has been measured in a prospective clinical trial Acupuncture appear to work to relieve “hot flashes” in men on LHRH agonists
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acupuncture, cancer, hormone, news, prostate, testosterone, therapy, update, zoledronic acid | Leave a Comment »
For those who are interested in following the abiraterone story in more detail, Bernie Boyce has started a blog on his experiences in enrolling in and (he hopes) participating in the Phase III clinical trial of abiraterone under the supervision of Dr. de Bono at the Royal Marsden Hospital in the UK.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Add new tag, cancer, hormone, prostate, refractory | 3 Comments »
In today’s prostate cancer news: More on the effects of hormone therapy on cognitive function and The application to market satraplatin has been withdraw in Europe
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, cognitive function, hormone, hormone refractory, prostate, satraplatin, therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site